Cibus, Inc. entered into investment agreement with AstraZeneca PLC to subscribe for 16,000,000 ordinary shares at a price of $5 per share for gross proceeds of $80 million on November 01, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.59 USD | -.--% | +2.93% | -10.44% |
05-09 | Cibus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Transcript : Cibus, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.44% | 397M | |
+12.50% | 228B | |
+14.52% | 196B | |
+17.51% | 141B | |
+28.96% | 110B | |
+1.25% | 65.88B | |
+18.16% | 54.3B | |
+7.63% | 52.39B | |
+10.95% | 45.22B | |
+5.10% | 37.12B |
- Stock Market
- Equities
- CLXT Stock
- News CALYXTPAR
- Cibus, Inc. announced that it expects to receive $80 million in funding